Astellas Pharma Inc.

4503.TJapan

15 filed reports · 354 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

¥2.14T

FY2026 · to Mar 31, 2026

up +11.9% vs ¥1.91T

Half-year report

Net income

¥292B

FY2026 · to Mar 31, 2026

up +475% vs ¥50.7B

Annual report

Operating income

¥383B

FY2026 · to Mar 31, 2026

up +832% vs ¥41B

Annual report

Latest half year

Revenue

¥1.27T

H1 FY2027 · to Sep 30, 2026

up +23.4% vs ¥1.03T

Half-year report

Net income

¥242B

H1 FY2027 · to Sep 30, 2026

up +63.6% vs ¥148B

Half-year report

Operating income

¥317B

H1 FY2027 · to Sep 30, 2026

up +58.8% vs ¥199B

Half-year report

Filed reports

15 reports · Dec 2021 to Sep 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Annual · annual securities reportEDINET41,559Mar 2022 to Mar 2026
Half Year · half-year securities reportEDINET3608Sep 2024 to Sep 2026
Q3 · quarterly securities reportEDINET3712Dec 2021 to Dec 2023
Half Year · quarterly securities reportEDINET2436Sep 2022 to Sep 2023
Q1 · quarterly securities reportEDINET2412Jun 2022 to Jun 2023
Annual · amended annual securities reportEDINET1308Mar 2023

Documents

PeriodTypePeriod endPublishedFactsSource
FY2027 H1half-year securities report2026-09-302026-11-06251Open
FY2026annual securities report2026-03-312026-06-16635Open
FY2026 H1half-year securities report2025-09-302025-11-06176Open
FY2025annual securities report2025-03-312025-06-16314Open
FY2025 H1half-year securities report2024-09-302024-11-06181Open
FY2024annual securities report2024-03-312024-06-20305Open
FY2024 Q3quarterly securities report2023-12-312024-02-06314Open
FY2024 H1quarterly securities report2023-09-302023-11-07238Open
FY2024 Q1quarterly securities report2023-06-302023-08-07248Open
FY2023amended annual securities report2023-03-312024-01-16308Open
FY2023 Q3quarterly securities report2022-12-312023-02-08201Open
FY2023 H1quarterly securities report2022-09-302022-11-08198Open

Financial data

354 concepts · 4,035 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

IFRS230 concepts · 3,352 facts · Mar 2020 to Sep 2026

  • Comprehensive Income Attributable to Owners of Parent37 · Mar 2020 to Sep 2026
  • EPS (Basic)37 · Mar 2020 to Sep 2026
  • EPS (Diluted)37 · Mar 2020 to Sep 2026
  • Pretax Income37 · Mar 2020 to Sep 2026
  • Profit Attributable to Owners of Parent37 · Mar 2020 to Sep 2026
  • Revenue37 · Mar 2020 to Sep 2026
  • Cash and Equivalents33 · Mar 2020 to Sep 2026
  • Stockholders Equity33 · Mar 2020 to Sep 2026
  • Equity Attributable to Owners of Parent30 · Mar 2020 to Sep 2026
  • Financing Cash Flow30 · Mar 2020 to Sep 2026
  • Investing Cash Flow30 · Mar 2020 to Sep 2026
  • Operating Cash Flow30 · Mar 2020 to Sep 2026
  • Ratio of owners' equity to gross assets (IFRS), Key financial data30 · Mar 2020 to Sep 2026
  • Total Assets30 · Mar 2020 to Sep 2026
  • Amoritisation of intangible assets26 · Dec 2020 to Sep 2026
  • Basic earnings (loss) per share (IFRS), Key financial data26 · Dec 2020 to Sep 2026
  • Capital surplus (IFRS)26 · Mar 2021 to Sep 2026
  • Cost of Revenue26 · Dec 2020 to Sep 2026
  • Deferred tax assets (IFRS)26 · Mar 2021 to Sep 2026
  • Deferred tax liabilities (IFRS)26 · Mar 2021 to Sep 2026
  • Equity attributable to owners of parent (IFRS), Key financial data26 · Mar 2021 to Sep 2026
  • Exchange differences on translation of foreign operations (net of tax), Items that may be reclassified to profit or loss - OCI (IFRS)26 · Dec 2020 to Sep 2026
  • Finance costs (IFRS)26 · Dec 2020 to Sep 2026
  • Finance income (IFRS)26 · Dec 2020 to Sep 2026

GAAP123 concepts · 673 facts · Mar 2020 to Mar 2026

  • Dividend paid per share7 · Mar 2020 to Mar 2026
  • EPS (Basic)7 · Mar 2020 to Mar 2026
  • EPS (Diluted)7 · Mar 2020 to Mar 2026
  • Equity-to-asset ratio, Key financial data7 · Mar 2020 to Mar 2026
  • Interim dividend paid per share7 · Mar 2020 to Mar 2026
  • Net Assets7 · Mar 2020 to Mar 2026
  • Net assets, Key financial data7 · Mar 2020 to Mar 2026
  • Net assets per share7 · Mar 2020 to Mar 2026
  • Net Income7 · Mar 2020 to Mar 2026
  • Number of employees7 · Mar 2020 to Mar 2026
  • Ordinary profit (loss), Key financial data7 · Mar 2020 to Mar 2026
  • Payout ratio7 · Mar 2020 to Mar 2026
  • Price-earnings ratio, Key financial data7 · Mar 2020 to Mar 2026
  • Rate of return on equity, Key financial data7 · Mar 2020 to Mar 2026
  • Revenue7 · Mar 2020 to Mar 2026
  • Share capital, Key financial data7 · Mar 2020 to Mar 2026
  • Total Assets7 · Mar 2020 to Mar 2026
  • Total number of issued shares7 · Mar 2020 to Mar 2026
  • Accounts payable - other6 · Mar 2021 to Mar 2026
  • Accounts payable - trade6 · Mar 2021 to Mar 2026
  • Accounts receivable - trade6 · Mar 2021 to Mar 2026
  • Accrued expenses6 · Mar 2021 to Mar 2026
  • Allowance for doubtful accounts-IOA-by group6 · Mar 2021 to Mar 2026
  • Buildings, net6 · Mar 2021 to Mar 2026

Segment1 concept · 10 facts · Mar 2022 to Mar 2026

  • Number of employees10 · Mar 2022 to Mar 2026

Segments

10 facts

Figures broken down by business line, region, product or another axis the company reports on.

Operating segments1 member · 10 facts

  • PharmaceuticalReportableSegmentMember10 · Mar 2022 to Mar 2026

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Astellas Pharma Inc. (4503.T) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.